Sen. Glenn medical radiation hearing
This article was originally published in The Gray Sheet
Executive SummarySen. John Glenn's (D-Ohio) Governmental Affairs Committee postpones hearing on regulation of medical radiation by FDA and the Nuclear Regulatory Commission. The hearing, originally scheduled for April 22 ("The Gray Sheet" March 22, p. 4), is tentatively slated for late May. FDA Center for Devices and Radiological Health Director Bruce Burlington will give testimony on behalf of FDA. NRC commissioners and members of the National Conference of Radiation Control Program Directors also are expected to testify.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Bangladesh’s Beximco will market Mylan’s biosimilars in its domestic market, under a deal that has just been struck between the two companies. The Ogivri trastuzumab biosimilar, co-developed by Mylan and Biocon, will be the first product launched as part of the collaboration.